UPCC 02818: A Phase I/IB Study of Avelumab in Combination with Gemcitabine for Advanced Renal Cell Carcinoma with Sarcomatoid Differentiation

Site Image

Study Overview

This study is being done because doctors are trying to develop better methods for treating kidney cancer that has spread to other organs in the body. This study will evaluate the initial safety and effectiveness of an investigational drug, avelumab, given in combination with a chemotherapy drug (gemcitabine) that is sometimes used to treat certain kidney cancers.

  • Study Identifier: 829195

Recruitment Status

Enrolling By Invitation

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu